Dendritic cells decreased the concomitant expanded tregs and tregs related IL-35 in cytokine-induced killer cells and increased their cytotoxicity against leukemia cells

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Pan, Ying ^a   Tao, Qianshan ^a   Wang, Huiping ^a   Xiong, Shudao ^a   Zhang, Rui ^a   Chen, Tianping ^a   Tao, Lili ^a   Zhai, Zhimin ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; INTERLEUKIN 10; INTERLEUKIN 35; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; INTERLEUKIN DERIVATIVE; INTERLEUKIN-35, HUMAN;

ADULT; ARTICLE; CANCER CELL CULTURE; CELL EXPANSION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOTOXICITY; DENDRITIC CELL; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; UPREGULATION; CELL CULTURE; COCULTURE; CYTOLOGY; IMMUNOLOGY; K562 CELL LINE; LEUKEMIA; LYMPHOCYTE COUNT; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ADULT; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINE-INDUCED KILLER CELLS; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HUMANS; INTERLEUKINS; K562 CELLS; LEUKEMIA; LYMPHOCYTE COUNT; T-LYMPHOCYTES, REGULATORY;

EID: 84899413645     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093591     Document Type: Article

References (28)

1. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL (1991) Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174: 139-149.
2. Mesiano G, Todorovic M, Gammaitoni L, Leuci V, Giraudo Diego L, et al. (2012) Cytokine induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther 12: 673-684.
3. Olioso P, Giancola R, Di Riti M, Contento A, Accorsi P, et al. (2009) Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol 27: 130-139.
4. Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG (2011) Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC).J Cancer Res Clin Oncol 137: 305-310.
5. Jiang J, Wu C, Lu B (2013) Cytokine-induced killer cells promote antitumor immunity. J Transl Med 11:83.doi: 10.1186/1479-5876-11-836.
6. Sakaguchi S, Vignali DA, Rudensky AY, Niec RE, Waldmann H (2013) The plasticity and stability of regulatory T cells. Nat Rev Immunol 13: 461-467.
7. Whiteside TL, Schuler P, Schilling B (2012) Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther 12: 1383-1397.
8. Whiteside TL (2012) What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol 22: 327-334.
9. + regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients. J Clin Immunol 27: 317-326.
10. Lin G, Wang J, Lao X, Wang J, Li L, et al. (2012) Interleukin-6 inhibits regulatory T cells and improves the proliferation and cytotoxic activity of cytokine-induced killer cells. J Immunother 35: 337-343.
11. + cells in cytokine-induced killer cells. Zhonghua Yi Xue Za Zhi 85: 3134-3138.
12. Märten A, Ziske C, Schöttker B, Renoth S, Weineck S, et al. (2001) Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother 24: 502-510. (Pubitemid 33104869)
13. + cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma. Cancer Immunol Immunother 53: 1018-1026.
14. + T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med 197: 111-119.
15. Schmitt EG, Williams CB (2013) Generation and function of induced regulatory T cells. Front Immunol 4:152. doi: 10.3389/fimmu.2013.00152.
16. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, et al. (2007) The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450: 566-569. (Pubitemid 350190247)
17. Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, et al. (2007) IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 37: 3021-3029. (Pubitemid 350131282)
18. Collison LW, Vignali DA (2008) Interleukin-35: odd one out or part of the family? Immunol Rev 226: 248-262.
19. Chaturvedi V, Collison LW, Guy CS, Workman CJ, Vignali DA (2011) Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol 186: 6661-6666.
20. Bardel E, Larousserie F, Charlot-Rabiega P, Coulomb-L'Herminé A, Devergne O (2008) Human CD4+ CD25+ Foxp3+ regulatory T cells do not constitutively express IL-35. J Immunol 181: 6898-6905.
21. Wang Z, Liu JQ, Liu Z, Shen R, Zhang G, et al. (2013) Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol 190: 2415-2423.
22. Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, et al. (1993) Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 21: 1673-1679. (Pubitemid 24223014)
23. Thanendrarajan S, Kim Y, Schmidt-Wolf I (2012) New adoptive immunotherapy strategies for solid tumours with CIK cells. Expert Opin Biol Ther 12: 565- 572.
24. + regulatory T cells and for expansion of these cells. J Immunol 178: 2018-2027.
25. + T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother 28: 120-128.
26. Shevach EM (2012) Application of IL-2 therapy to target T regulatory cell function. Trends Immunol 33:626-632.
27. + T cells. Nat Immunol 8: 1353-1362.
28. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, et al. (2010) IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 11: 1093-1101.